Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CARPACCIO
2024-512297-96-01Phase 2Authorised
- Sponsor
- Unicancer
- Start
- Oct 2024
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cetuximab, paclitaxel and carboplatin in head and neck squamous cell carcinoma (HNSCC), sponsored by Unicancer. Primary endpoint: Objective response within 12 months. Planned start Oct 2024; status: authorised.
02
Drugs
cetuximabpaclitaxelcarboplatin
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2024-512297-96-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512297-96-01.